Fri, Mar 6, 2015, 5:25 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • dinepat203 dinepat203 Dec 12, 2012 8:54 PM Flag

    Why pharma Giants wants ISIS? GSK,SANOFI-GENZYME,BIIB, ASTRAZENICA...wants newer antisense molecules..,

    Antisense oligonucleotides (ASO) are becoming more widely accepted as potential therapeutics for
    various diseases. Antisense therapy has emerged as an exciting and promising strategy for the
    treatment of various diseases. Antisense are different from conventional drugs that are designed to
    interact with protein molecule. Antisense drugs have more selective action and they have the potential
    to be more effective and less toxic than conventional drugs. Recent clinical trials confirm the ability of
    antisense to significantly suppress target-gene expression. Antisense oligonucleotides are usually
    highly selective and thus produce fewer adverse effects than conventional therapeutics. Antisense
    technology might be a gateway to the treatment of diseases by targeting the expression of genes rather
    than permanently altering them. Antisense oligonucleotides can alter target gene expression by binding
    to RNA. Once bound, the ASO either disables or induces the degradation of the target RNA. This
    technology may be used to treat various conditions including cancer, diabetes, and hypertension, as
    well as autoimmune and cardiovascular diseases. ASOs are potentially potent, selective and welltolerated
    drugs. The current status and future direction of several antisense drugs that have potential
    clinical use in treatment of various diseases are reviewed in latest Academic Journal publication.

    Sentiment: Strong Buy

 
ISIS
70.44-1.32(-1.84%)Mar 6 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.